Added to YB: 2023-12-21
Pitch date: 2023-12-13
ROIV [bullish]
Roivant Sciences Ltd.
+100%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
Market Cap
$14.1B
Pitch Price
$11.05
Price Target
24.00 (+9%)
Dividend
N/A
EV/EBITDA
-9.39
P/E
-20.20
EV/Sales
505.07
Sector
Biotechnology
Category
value
Show full summary:
ROIVANT SCIENCES LTD - ROIV
$ROIV undervalued: $7B Roche deal+$7B cash/invs ($4.12/sh IMVT stake) = $12/sh vs $10.35 now ignoring other assets eg LNP litigation ($5-10/sh), Dermavant products, etc. Base $15.61 (51% upside), blue sky $24+ (100%+). Risks low as floor ~current price. Tax/mgmt tailwinds.
Read full article (18 min)